Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08MJO
|
|||
| Former ID |
DCL000743
|
|||
| Drug Name |
CDP323
|
|||
| Synonyms |
Zaurategrast; 455264-31-0; (S)-3-(4-((2,7-Naphthyridin-1-yl)amino)phenyl)-2-((2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino)propanoic acid; UNII-06A0IC74I3; 06A0IC74I3; C26H25BrN4O3; Zaurategrast [INN]; SCHEMBL2976322; CTK8C0588; DTXSID90196547; MolPort-023-332-826; KS-00001DY0; ANW-64932; 6274AB; ZINC100041912; AKOS016005046; CS-0322; N-(2-Bromo-3-oxospiro[3.5]non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-L-phenylalanine; NCGC00378753-01
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40] | Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [1] | ||
| Company |
UCB; Biogen Idec
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H29BrN4O3
|
|||
| Canonical SMILES |
CCOC(=O)C(CC1=CC=C(C=C1)NC2=NC=CC3=C2C=NC=C3)NC4=C(C(=O)C45CCCCC5)Br
|
|||
| InChI |
1S/C28H29BrN4O3/c1-2-36-27(35)22(33-24-23(29)25(34)28(24)12-4-3-5-13-28)16-18-6-8-20(9-7-18)32-26-21-17-30-14-10-19(21)11-15-31-26/h6-11,14-15,17,22,33H,2-5,12-13,16H2,1H3,(H,31,32)/t22-/m0/s1
|
|||
| InChIKey |
QCYAXXZCQKMTMO-QFIPXVFZSA-N
|
|||
| CAS Number |
CAS 455264-30-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. | |||
| REF 2 | Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.PLoS One.2013;8(3):e58438. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.